Trial Profile
A Single Ascending, Placebo-controlled, Double-blind Study in Healthy Male Subjects to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the New Humanized Monoclonal Antibody CaCP29
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Vilobelimab (Primary)
- Indications Sepsis
- Focus Adverse reactions
- Sponsors InflaRx
- 24 Apr 2014 New trial record